- US12599594utility2026Treatment of Fabry Disease in Ert-naïve and Ert-experienced Patients0 cites
- US12599595utility2026Dosing Regimens for the Treatment of Lysosomal Storage Diseases Using Pharmacological Chaperones0 cites
- US12594268utility2026Methods of Treating Fabry Disease in Patients Having a Mutation in the GLA Gene0 cites
- US12419937utility2025High Concentration Alpha-glucosidase Compositions for the Treatment of Pompe Disease0 cites
- US12414944utility2025Methods of Treating Fabry Disease in Patients Having the G9331A Mutation in the GLA Gene0 cites
- US12414985utility2025Augmented Acid Alpha-glucosidase for the Treatment of Pompe Disease0 cites
- USD1087752design2025Drug Package0 cites
- USD1082532design2025Drug Package0 cites
- US12280042utility2025Methods of Treating Fabry Patients Having Renal Impairment0 cites
- US12275703utility2025Highly Purified Batches of Pharmaceutical Grade Migalastat and Methods of Producing the Same0 cites
- US12246062utility2025Recombinant Human Acid Alpha-glucosidase0 cites
- US12109205utility2024Methods of Treating Fabry Patients Having Renal Impairment0 cites
- US12070453utility2024Treatment of Fabry Disease in Ert-naïve and Ert-experienced Patients0 cites
- US12064485utility2024Disulfide Bond Stabilized Polypeptide Compositions and Methods of Use0 cites
- US12042488utility2024Methods of Treating Fabry Patients Having Renal Impairment0 cites
- US12042489utility2024Methods of Treating Fabry Patients Having Renal Impairment0 cites
- US12042490utility2024Methods of Treating Fabry Patients Having Renal Impairment0 cites
- US11903938utility2024Methods of Treating Fabry Patients Having Renal Impairment0 cites
- US11833164utility2023Methods of Treating Fabry Disease in Patients Having a Mutation in the GLA Gene0 cites
Page 1 of 2Next →